2024 World Conference on Lung Cancer (WCLC) - Posters-P4.07F.03 A Cost-Effective Tumor-Informed ctDNA Analysis for MRD Detection in Resected NSCLC With Common Driver Genes

P4.07F.03 A Cost-Effective Tumor-Informed ctDNA Analysis for MRD Detection in Resected NSCLC With Common Driver Genes

Pdf Summary

The study, presented by Ran Zhong from The First Affiliated Hospital of Guangzhou Medical University, explores the use of circulating tumor DNA (ctDNA) for detecting molecular residual disease (MRD) in resected non-small cell lung cancer (NSCLC) patients, focusing on the common driver mutations, EGFR and KRAS. Digital droplet PCR (ddPCR) is highlighted for its specificity in mutation detection within cell-free DNA.<br /><br />In this ongoing prospective study, 300 patients with stage I to III NSCLC and confirmed EGFR or KRAS mutations were enrolled. ctDNA was detected using ddPCR from plasma samples collected post-operation, at intervals of 3 to 6 months. The study examined MRD results alongside factors like patient age, lung cancer type, gene mutations, and TNM stage.<br /><br />By January 2024, 695 blood samples had been analyzed. Of the patients, 54% had EGFR L858R mutations, 34% EGFR 19del, 10% KRAS, and 1% had multiple mutations. Most participants were diagnosed with Stage IA NSCLC, with follow-ups extended up to 3 years. During this period, 12 patients experienced a relapse. Subgroup analyses of MRD positivity rates were performed based on different variables, offering insights on their correlation with MRD status.<br /><br />The study concludes that ddPCR technology shows promise for evaluating ctDNA MRD in patients with resected NSCLC possessing common mutations. Given the high prevalence of these mutations in the Chinese population, the study suggests that such tumor-informed strategies could serve as cost-effective MRD monitoring tools. Additional research is required to further validate these findings and assess their practical application in clinical settings. Ran Zhong encourages further collaboration and discussion on the topic.

Asset Subtitle

Ran Zhong

Meta Tag

Speaker Ran Zhong

Topic Early-Stage NSCLC

Keywords

circulating tumor DNA

molecular residual disease

non-small cell lung cancer

EGFR mutations

KRAS mutations

digital droplet PCR

cell-free DNA

NSCLC stages

MRD monitoring

tumor-informed strategies